The contribution of hypertension to diabetic nephropathy and retinopathy: The role of inflammation and oxidative stress

Hypertension Research

Volumn 34, Issue 4, 2011, Pages 413-422

  De Faria, José Butori Lopes ^a   Silva, Kamila Cristina ^a   Lopes De Faria, Jacqueline Mendonça ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

diabetic nephropathy; diabetic retinopathy; inflammation; oxidative stress

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN CONVERTING ENZYME 2; CANDESARTAN; ENALAPRIL; IRBESARTAN; LOSARTAN; PLACEBO; PRORENIN; PRORENIN RECEPTOR; RENIN; SPIRONOLACTONE;

ANTIHYPERTENSIVE THERAPY; CHRONIC INFLAMMATION; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DRUG MECHANISM; EVIDENCE BASED MEDICINE; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; RISK REDUCTION;

COMORBIDITY; DIABETIC NEPHROPATHIES; DIABETIC RETINOPATHY; HUMANS; HYPERTENSION; INFLAMMATION; KIDNEY; OXIDATIVE STRESS; RETINA;

EID: 79953728467     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2010.263     Document Type: Review

References (157)

1. Anonymous. National High Blood Pressure Education Program Working Group report on hypertension in diabetes. Hypertension 1994; 23: 145-158.
2. Geiss LS, Rolka DB, Engelgau MM. Elevated blood pressure among U.S. adults with diabetes, 1988-1994. Am J Prev Med 2002; 22: 42-48. (Pubitemid 34037011)
3. Jensen T, Borch-Johnsen K, Deckert T. Changes in blood pressure and renal function in patients with type I (insulin-dependent) diabetes mellitus prior to clinical diabetic nephropathy. Diabetes Res 1987; 4: 159-162. (Pubitemid 17108070)
4. Parving HH. Controlling hypertension in diabetes. Acta Diabetol 2002; 39: S35-S40.
5. Tarnow L, Rossing P, Gall MA, Nielsen FS, Parving HH. Prevalence of arterial hypertension in diabetic patients before and after the JNC-V. Diabetes Care 1994; 17: 1247-1251. (Pubitemid 24324966)
6. Stratton IM, Cull CA, Adler AI, Matthews DR, Neil HA, Holman RR. Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75). Diabetologia 2006; 49: 1761-1769. (Pubitemid 44025030)
7. The UKPDS Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998; 317: 703-713.
8. Zoungas S, de Galan BE, Ninomiya T, Grobbee D, Hamet P, Heller S, MacMahon S, Marre M, Neal B, Patel A, Woodward M, Chalmers J, Cass A, Glasziou P, Harrap S, Lisheng L, Mancia G, Pillai A, Poulter N, Perkovic V, Travert F, ADVANCE Collaborative Group. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: new results from the ADVANCE trial. Diabetes Care 2009; 32: 2068-2074.
9. Giunti S, Barit D, Cooper ME. Mechanisms of diabetic nephropathy: role of hypertension. Hypertension 2006; 48: 519-526. (Pubitemid 44843845)
10. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002; 61: 1086-1097. (Pubitemid 34175478)
11. Thomas MC, Atkins RC. Blood pressure lowering for the prevention and treatment of diabetic kidney disease. Drugs 2006; 66: 2213-2234. (Pubitemid 44878529)
12. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology 2008; 115: 1859-1868.
13. Klein R, Lee KE, Gangnon RE, Klein BE. The 25-year incidence of visual impairment in type 1 diabetes mellitus the wisconsin epidemiologic study of diabetic retinopathy. Ophthalmology 2010; 117: 63-70.
14. Rodrigues TC, Canani LH, Viatroski RS, Hoffmann LH, Esteves JF, Gross JL. Masked hypertension, nocturnal blood pressure and retinopathy in normotensive patients with type 1 diabetes. Diabetes Res Clin Pract 2010; 87: 240-245.
15. Körner A, Jaremko G, Eklöf AC, Aperia A. Rapid development of glomerulosclerosis in diabetic Dahl salt-sensitive rats. Diabetologia 1997; 40: 367-373. (Pubitemid 27132606)
16. Mauer SM, Steffes MW, Azar S, Sandberg SK, Brown DM. The effects of Goldblatt hypertension on development of the glomerular lesions of diabetes mellitus in the rat. Diabetes 1978; 27: 738-744. (Pubitemid 8393564)
17. Wakisaka M, Nunoi K, Iwase M, Kikuchi M, Maki Y, Yamamoto K, Sadoshima S, Fujishima M. Early development of nephropathy in a new model of spontaneously hypertensive rat with non-insulin-dependent diabetes mellitus. Diabetologia 1988; 31: 291-296.
18. Cooper ME, Allen TJ, O'Brien RC, Macmillan PA, Clarke B, Jerums G, Doyle AE. Effects of genetic hypertension on diabetic nephropathy in the rat-functional and structural characteristics. J Hypertens 1988; 6: 1009-1016. (Pubitemid 19041649)
19. Dosso AA, Leuenberger PM, Rungger-Brändle E. Remodeling of retinal capillaries in the diabetic hypertensive rat. Invest Ophthalmol Vis Sci 1999; 40: 2405-2410. (Pubitemid 29418398)
20. Hammes HP, Brownlee M, Edelstein D, Saleck M, Martin S, Federlin K. Aminogua-nidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat. Diabetologia 1994; 37: 32-35. (Pubitemid 24044704)
21. Gin T, Joon TL, Panagiotopoulos S, Cooper M, Taylor H, Jerums G. Organ specificity of antihypertensive therapy on ocular albumin vascular clearance and albuminuria in the hypertensive diabetic rat. Invest Ophthalmol Vis Sci 1996; 37: 281-289. (Pubitemid 26057054)
22. Righetti AE, Boer-Lima PA, Lopes de Faria JB. The presence of genetic hypertension stimulates early renal accumulation of fibronectin in experimental diabetes mellitus. Diabetologia 2001; 44: 2088-2091. (Pubitemid 33124055)
23. Lopes de Faria JM, Silva KC, Boer PA, Cavalcanti TC, Rosales MA, Ferrari AL, Lopes de Faria JB. A decrease in retinal progenitor cells is associated with early features of diabetic retinopathy in a model that combines diabetes and hypertension. Mol Vis 2008; 14: 1680-1691.
24. Wolf G. Cell cycle regulation in diabetic nephropathy. Kidney Int 2000; 77: S59-S66.
25. Wolf G, Schroeder R, Thaiss F, Ziyadeh FN, Helmchen U, Stahl RA. Glomerular expression of p27Kip1 in diabetic db/db mouse: role of hyperglycemia. Kidney Int 1998; 53: 869-879. (Pubitemid 28155659)
26. Wolf G, Schanze A, Stahl RA, Shankland SJ, Amann K. p27(Kip1) knockout mice are protected from diabetic nephropathy: evidence for p27(Kip1) haplotype insufficiency. Kidney Int 2005; 68: 1583-1589. (Pubitemid 43169903)
27. Silveira LA, Bacchi CE, Pinto GA, De Faria JB. The genetics of hypertension modifies the renal cell replication response induced by experimental diabetes. Diabetes 2002; 51: 1529-1534. (Pubitemid 34826621)
28. Carmines PK. The renal vascular response to diabetes. Curr Opin Nephrol Hypertens 2010; 19: 85-90.
29. Gruden G, Zonca S, Hayward A, Thomas S, Maestrini S, Gnudi L, Viberti GC. Mechanical stretch-induced fibronectin and transforming growth factor-beta1 production in human mesangial cells is p38 mitogen-activated protein kinase-dependent. Diabetes 2000; 49: 655-661. (Pubitemid 30183756)
30. Rassam SM, Patel V, Kohner EM. The effect of experimental hypertension on retinal vascular autoregulation in humans: a mechanism for the progression of diabetic retinopathy. Exp Physiol 1995; 80: 53-68.
31. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, Nguyen HV, Aiello LM, Ferrara N, King GL. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480-1487. (Pubitemid 24356306)
32. Seko Y, Seko Y, Fujikura H, Pang J, Tokoro T, Shimokawa H. Induction of vascular endothelial growth factor after application of mechanical stress to retinal pigment epithelium of the rat in vitro. Invest Ophthalmol Vis Sci 1999; 40: 3287-3291.
33. Suzuma I, Hata Y, Clermont A, Pokras F, Rook SL, Suzuma K, Feener EP, Aiello LP. Cyclic stretch and hypertension induce retinal expression of vascular endothelial growth factor and vascular endothelial growth factor receptor-2: potential mechanisms for exacerbation of diabetic retinopathy by hypertension. Diabetes 2001; 50: 444-454. (Pubitemid 32140442)
34. Suzuma I, Suzuma K, Ueki K, Hata Y, Feener EP, King GL, Aiello LP. Stretch-induced retinal vascular endothelial growth factor expression is mediated by phosphatidylinositol 3-kinase and protein kinase C (PKC)-zeta but not by stretch-induced ERK1/2, Akt, Ras, or classical/novel PKC pathways. J Biol Chem 2002; 277: 1047-1057. (Pubitemid 34968850)
35. Suzuma I, Murakami T, Suzuma K, Kaneto H, Watanabe D, Ojima T, Honda Y, Takagi H, Yoshimura N. Cyclic stretch-induced reactive oxygen species generation enhances apoptosis in retinal pericytes through c-jun NH2-terminal kinase activation. Hypertension 2007; 49: 347-354. (Pubitemid 46143012)
36. Beltramo E, Berrone E, Giunti S, Gruden G, Perin PC, Porta M. Effects of mechanical stress and high glucose on pericyte proliferation, apoptosis and contractile phenotype. Exp Eye Res 2006; 83: 989-994. (Pubitemid 44292694)
37. Mizutani M, Kern TS, Lorenzi M. Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy. J Clin Invest 1996; 97: 2883-2890. (Pubitemid 26197103)
38. Pfister F, Feng Y, vom Hagen F, Hoffmann S, Molema G, Hillebrands JL, Shani M, Deutsch U, Hammes HP. Pericyte migration: a novel mechanism of pericyte loss in experimental diabetic retinopathy. Diabetes 2008; 57: 2495-2502.
39. Yasuda T, Kondo S, Homma T, Harris RC. Regulation of extracellular matrix by mechanical stress in rat glomerular mesangial cells. J Clin Invest 1996; 98: 1991-2000. (Pubitemid 26376286)
40. Cortes P, Zhao X, Riser BL, Narins RG. Role of glomerular mechanical strain in the pathogenesis of diabetic nephropathy. Kidney Int 1997; 51: 57-68. (Pubitemid 27064522)
41. Riser BL, Ladson-Wofford S, Sharba A, Cortes P, Drake K, Guerin CJ, Yee J, Choi ME, Segarini PR, Narins RG. TGF-beta receptor expression and binding in rat mesangial cells: modulation by glucose and cyclic mechanical strain. Kidney Int 1999; 56: 428-439. (Pubitemid 29353140)
42. Riser BL, Denichilo M, Cortes P, Baker C, Grondin JM, Yee J, Narins RG. Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. J Am Soc Nephrol 2000; 11: 25-38. (Pubitemid 30020423)
43. Giunti S, Pinach S, Arnaldi L, Viberti G, Perin PC, Camussi G, Gruden G. The MCP-1/ CCR2 system has direct proinflammatory effects in human mesangial cells. Kidney Int 2006; 69: 856-863.
44. Gruden G, Setti G, Hayward A, Sugden D, Duggan S, Burt D, Buckingham RE, Gnudi L, Viberti G. Mechanical stretch induces monocyte chemoattractant activity via an NF-kappaB-dependent monocyte chemoattractant protein-1-mediated pathway in human mesangial cells: inhibition by rosiglitazone. J Am Soc Nephrol 2005; 16: 688-696. (Pubitemid 41725105)
45. Kuroiwa T, Lee EG, Danning CL, Illei GG, McInnes IB, Boumpas DT. CD40 ligand-activated human monocytes amplify glomerular inflammatory responses through soluble and cell-tocell contact-dependent mechanisms. J Immunol 1999; 163: 2168-2175. (Pubitemid 29382224)
46. Mene P, Pugliese F, Cinotti GA. Adhesion of U-937 monocytes induces cytotoxic damage and subsequent proliferation of cultured human mesangial cells. Kidney Int 1996; 50: 417-423. (Pubitemid 26274367)
47. Gruden G, Thomas S, Burt D, Zhou W, Chusney G, Gnudi L, Viberti G. Interaction of angiotensin II and mechanical stretch on vascular endothelial growth factor production by human mesangial cells. J Am Soc Nephrol 1999; 10: 730-737. (Pubitemid 29149522)
48. Thomas S, Vanuystel J, Gruden G, Rodŕguez V, Burt D, Gnudi L, Hartley B, Viberti G. Vascular endothelial growth factor receptors in human mesangium in vitro and in glomerular disease. J Am Soc Nephrol 2000; 11: 1236-1243. (Pubitemid 30416219)
49. Amemiya T, Sasamura H, Mifune M, Kitamura Y, Hirahashi J, Hayashi M, Saruta T. Vascular endothelial growth factor activates MAP kinase and enhances collagen synthesis in human mesangial cells. Kidney Int 1999; 56: 2055-2063. (Pubitemid 30004734)
50. Gnudi L, Viberti G, Raij L, Rodriguez V, Burt D, Cortes P, Hartley B, Thomas S, Maestrini S, Gruden G. GLUT-1 overexpression: link between hemodynamic and metabolic factors in glomerular injury? Hypertension 2003; 42: 19-24. (Pubitemid 36842231)
51. Heilig CW, Concepcion LA, Riser BL, Freytag SO, Zhu M, Cortes P. Overexpression of glucose transporters in rat mesangial cells cultured in a normal glucose milieu mimics the diabetic phenotype. J Clin Invest 1995; 96: 1802-1814.
52. Shankland SJ. The podocyte's response to injury: role in proteinuria and glomerulo-sclerosis. Kidney Int 2006; 69: 2131-2147. (Pubitemid 43882099)
53. White KE, Bilous RW. Structural alterations to the podocyte are related to proteinuria in type 2 diabetic patients. Nephrol Dial Transplant 2004; 19: 1437-1440. (Pubitemid 38786736)
54. Endlich N, Kress KR, Reiser J, Uttenweiler D, Kriz W, Mundel P, Endlich K. Podocytes respond to mechanical stress in vitro. J Am Soc Nephrol 2001; 12: 413-422. (Pubitemid 32180009)
55. Endlich N, Endlich K. Stretch, tension and adhesion- adaptive mechanisms of the actin cytoskeleton in podocytes. Eur J Cell Biol 2006; 85: 229-234.
56. Dessapt C, Baradez MO, Hayward A, Dei Cas A, Thomas SM, Viberti G, Gnudi L. Mechanical forces and TGFbeta1 reduce podocyte adhesion through alpha3beta1 integrin downregulation. Nephrol Dial Transplant 2009; 24: 2645-2655.
57. Patey N, Halbwachs-Mecarelli L, Droz D, Lesavre P, Noel LH. Distribution of integrin subunits in normal human kidney. Cell Adhes Commun 1994; 2: 159-167. (Pubitemid 24215217)
58. Ruoslahti E. Integrins. J Clin Invest 1991; 87: 1-5.
59. Durvasula RV, Shankland SJ. Activation of a local renin angiotensin system in podocytes by glucose. Am J Physiol Renal Physiol 2008; 294: F830-F839.
60. Durvasula RV, Petermann AT, Hiromura K, Blonski M, Pippin J, Mundel P, Pichler R, Griffin S, Couser WG, Shankland SJ. Activation of a local tissue angiotensin system in podocytes by mechanical strain. Kidney Int 2004; 65: 30-39. (Pubitemid 38037489)
61. Miceli I, Burt D, Tarabra E, Camussi G, Perin PC, Gruden G. Stretch reduces nephrin expression via an angiotensin II-AT(1)-dependent mechanism in human podocytes: effect of rosiglitazone. Am J Physiol Renal Physiol 2010; 298: F381-F390.
62. Doublier S, Salvidio G, Lupia E, Ruotsalainen V, Verzola D, Deferrari G, Camussi G. Nephrin expression is reduced in human diabetic nephropathy: evidence for a distinct role for glycated albumin and angiotensin II. Diabetes 2003; 52: 1023-1030. (Pubitemid 36384273)
63. Bonnet F, Cooper ME, Kawachi H, Allen TJ, Boner G, Cao Z. Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension. Diabetologia 2001; 44: 874-877. (Pubitemid 32642460)
64. Amazonas RB, Sanita Rde A, Kawachi H, de Faria JB. Prevention of hypertension with or without renin-angiotensin system inhibition precludes nephrin loss in the early stage of experimental diabetes mellitus. Nephron Physiol 2007; 107: 57-64.
65. Gorin Y, Block K, Hernandez J, Bhandari B, Wagner B, Barnes JL, Abboud HE. Nox4 NAD(P)H oxidase mediates hypertrophy and fibronectin expression in the diabetic kidney. J Biol Chem 2005; 280: 39616-39626. (Pubitemid 41713921)
66. Susztak K, Raff AC, Schiffer M, Böttinger EP. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 2006; 55: 225-233. (Pubitemid 43343319)
67. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005; 54: 1615-1625. (Pubitemid 40770750)
68. Jones DP. Redefining oxidative stress. Antioxid Redox Signal 2006; 8: 1865-1879. (Pubitemid 44726359)
69. Halliwell B, Whiteman M. Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean? Br J Pharmacol 2004; 142: 231-255. (Pubitemid 38746160)
70. Hinokio Y, Suzuki S, Hirai M, Chiba M, Hirai A, Toyota T. Oxidative DNA damage in diabetes mellitus: its association with diabetic complications. Diabetologia 1999; 42: 995-998. (Pubitemid 29369608)
71. Nishikawa T, Sasahara T, Kiritoshi S, Sonoda K, Senokuchi T, Matsuo T, Kukidome D, Wake N, Matsumura T, Miyamura N, Sakakida M, Kishikawa H, Araki E. Evaluation of urinary 8-hydroxydeoxy-guanosine as a novel biomarker of macrovascular complications in type 2 diabetes. Diabetes Care 2003; 26: 1507-1512. (Pubitemid 36929187)
72. Hinokio Y, Suzuki S, Hirai M, Suzuki C, Suzuki M, Toyota T. Urinary excretion of 8-oxo-7, 8-dihydro-2¢-deoxyguanosine as a predictor of the development of diabetic nephro-pathy. Diabetologia 2002; 45: 877-882.
73. Wang Q, Pfister F, Dorn-Beineke A, Vom Hagen F, Lin J, Feng Y, Hammes HP. Low-dose erythropoietin inhibits oxidative stress and early vascular changes in the experimental diabetic retina. Diabetologia 2010; 53: 1227-1238.
74. Furuta T, Saito T, Ootaka T, Soma J, Obara K, Abe K, Yoshinaga K. The role of macrophages in diabetic glomerulosclerosis. Am J Kidney Dis 1993; 21: 480-485. (Pubitemid 23160508)
75. Utimura R, Fujihara CK, Mattar AL, Malheiros DM, Noronha IL, Zatz R. Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes. Kidney Int 2003; 63: 209-216. (Pubitemid 35463923)
76. Tone A, Shikata K, Sasaki M, Ohga S, Yozai K, Nishishita S, Usui H, Nagase R, Ogawa D, Okada S, Shikata Y, Wada J, Makino H. Erythromycin ameliorates renal injury via anti-inflammatory effects in experimental diabetic rats. Diabetologia 2005; 48: 2402-2411. (Pubitemid 41618933)
77. Yozai K, Shikata K, Sasaki M, Tone A, Ohga S, Usui H, Okada S, Wada J, Nagase R, Ogawa D, Shikata Y, Makino H. Methotrexate prevents renal injury in experimental diabetic rats via anti-inflammatory actions. J Am Soc Nephrol 2005; 16: 3326-3338. (Pubitemid 46179336)
78. Okada S, Shikata K, Matsuda M, Ogawa D, Usui H, Kido Y, Nagase R, Wada J, Shikata Y, Makino H. Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes. Diabetes 2003; 52: 2586-2593. (Pubitemid 37210549)
79. Chow FY, Nikolic-Paterson DJ, Ozols E, Atkins RC, Rollin BJ, Tesch GH. Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int 2006; 69: 73-80. (Pubitemid 43117741)
80. Kern TS. Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp Diabetes Res 2007; 2007: 95103.
81. McLeod DS, Lefer DJ, Merges C, Lutty GA. Enhanced expression of intracellular adhesion molecule-1 and P-selectin in the diabetic human retina and choroid. Am J Pathol 1995; 147: 642-653.
82. Limb GA, Hickman-Casey J, Hollifield RD, Chignell AH. Vascular adhesion molecules in vitreous from eyes with proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 1999; 40: 2453-2457. (Pubitemid 29418408)
83. Hernández C, Segura RM, Fonollosa A, Carrasco E, Francisco G, Simó R. Interleukin-8, monocyte chemoattractant protein-1 and IL-10 in the vitreous fluid of patients with proliferative diabetic retinopathy. Diabet Med 2005; 22: 719-722. (Pubitemid 40805892)
84. Silva KC, Pinto CC, Biswas SK, Souza DS, de Faria JB, de Faria JM. Prevention of hypertension abrogates early inflammatory events in the retina of diabetic hypertensive rats. Exp Eye Res 2007; 85: 123-129. (Pubitemid 47017272)
85. Calcutt NA, Cooper ME, Kern TS, Schmidt AM. Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. Nat Rev Drug Discov 2009; 8: 417-429.
86. Vaziri ND, Rodriguez-Iturbe B. Mechanisms of disease: oxidative stress and inflammation in the pathogenesis of hypertension. Nat Clin Pract Nephrol 2006; 2: 582-593. (Pubitemid 44465680)
87. Biswas SK, Peixoto EB, Souza DS, de Faria JB. Hypertension increases pro-oxidant generation and decreases antioxidant defense in the kidney in early diabetes. Am J Nephrol 2008; 28: 133-142. (Pubitemid 350126504)
88. DeRubertis FR, Craven PA, Melhem MF, Salah EM. Attenuation of renal injury in db/db mice overexpressing superoxide dismutase: evidence for reduced superoxide-nitric oxide interaction. Diabetes 2004; 53: 762-768. (Pubitemid 38270647)
89. Fujita H, Fujishima H, Chida S, Takahashi K, Qi Z, Kanetsuna Y, Breyer MD, Harris RC, Yamada Y, Takahashi T. Reduction of renal superoxide dismutase in progressive diabetic nephropathy. J Am Soc Nephrol 2009; 20: 1303-1313.
90. Peixoto EB, Pessoa BS, Biswas SK, Lopes de Faria JB. Antioxidant SOD mimetic prevents NADPH oxidase-induced oxidative stress and renal damage in the early stage of experimental diabetes and hypertension. Am J Nephrol 2009; 29: 309-318.
91. Ribaldo PD, Souza DS, Biswas SK, Block K, Lopes de Faria JM, Lopes de Faria JB. Green tea (Camellia sinensis) attenuates nephropathy by downregulating Nox4 NADPH oxidase in diabetic spontaneously hypertensive rats. J Nutr 2009; 139: 96-100.
92. Silva KC, Pinto CC, Biswas SK, de Faria JB, de Faria JM. Hypertension increases retinal inflammation in experimental diabetes: a possible mechanism for aggravation of diabetic retinopathy by hypertension. Curr Eye Res 2007; 32: 533-541. (Pubitemid 47039108)
93. Madsen-Bouterse SA, Kowluru RA. Oxidative stress and diabetic retinopathy: patho-physiological mechanisms and treatment perspectives. Rev Endocr Metab Disord 2008; 9: 315-327.
94. Kowluru RA, Odenbach S. Effect of long-term administration of alpha-lipoic acid on retinal capillary cell death and the development of retinopathy in diabetic rats. Diabetes 2004; 53: 3233-3238. (Pubitemid 39564500)
95. Du Y, Smith MA, Miller CM, Kern TS. Diabetes-induced nitrative stress in the retina, and correction by aminoguanidine. J Neurochem 2002; 80: 771-779. (Pubitemid 34809229)
96. Pinto CC, Silva KC, Biswas SK, Martins N, De Faria JB, De Faria JM. Arterial hypertension exacerbates oxidative stress in early diabetic retinopathy. Free Radic Res 2007; 41: 1151-1158. (Pubitemid 47470853)
97. Rosales MA, Silva KC, Lopes de Faria JB, Lopes de Faria JM. Exogenous SOD mimetic tempol ameliorates the early retinal changes restablishing the redox status in diabetic hypertensive rats. Invest Ophthalmol Vis Sci 2010; 51: 4327-4336.
98. Silva KC, Rosales MA, de Faria JB, de Faria JM. Reduction of inducible nitric oxide synthase via angiotensin receptor blocker prevents the oxidative retinal damage in diabetic hypertensive rats. Curr Eye Res 2010; 35: 519-528.
99. Silva KC, Rosales MA, Biswas SK, Lopes de Faria JB, Lopes de Faria JM. Diabetic retinal neurodegeneration is associated with mitochondrial oxidative stress and is improved by an angiotensin receptor blocker in a model combining hypertension and diabetes. Diabetes 2009; 58: 1382-1390.
100. Jung KH, Chu K, Lee ST, Kim SJ, Song EC, Kim EH, Park DK, Sinn DI, Kim JM, Kim M, Roh JK. Blockade of AT1 receptor reduces apoptosis, inflammation, and oxidative stress in normotensive rats with intracerebral hemorrhage. J Pharmacol Exp Ther 2007; 322: 1051-1058. (Pubitemid 47295814)
101. Anderson S. Role of local and systemic angiotensin in diabetic renal disease. Kidney Int Suppl 1997; 63: S107-S110. (Pubitemid 28020446)
102. Cooper ME. The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications. Am J Hypertens 2004; 17: 16S-20S. (Pubitemid 39469911)
103. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456-1462. (Pubitemid 23335891)
104. Mauer M, Zinman B, Gardiner R, Suissa S, Sinaiko A, Strand T, Drummond K, Donnelly S, Goodyer P, Gubler MC, Klein R. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009; 361: 40-51.
105. Chaturvedi N, Porta M, Klein R, Orchard T, Fuller J, Parving HH, Bilous R, Sjølie AK, DIRECT Programme Study Group. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebocontrolled trials. Lancet 2008; 372: 1394-1402.
106. Anonymous. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355: 253-259.
107. Ruggenenti P, Perna A, Ganeva M, Ene-Iordache B, Remuzzi G, BENEDICT Study Group. Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial. J Am Soc Nephrol 2006; 17: 3472-3481. (Pubitemid 44865289)
108. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P. Irbesartan in patients with type 2 diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.
109. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Shahinfar S, RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
110. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
111. Sjølie AK, Klein R, Porta M, Orchard T, Fuller J, Parving HH, Bilous R, Chaturvedi N. DIRECT programme study group: effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomized placebocontrolled trial. Lancet 2008; 372: 1385-1393.
112. Mehdi UF, Adams-Huet B, Raskin P, Vega GL, Toto RD. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol 2009; 20: 2641-2650.
113. Kang YS, Ko GJ, Lee MH, Song HK, Han SY, Han KH, Kim HK, Han JY, Cha DR. Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats. Nephrol Dial Transplant 2009; 24: 73-84.
114. Fujisawa G, Okada K, Muto S, Fujita N, Itabashi N, Kusano E, Ishibashi S. Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats. Kidney Int 2004; 66: 1493-1502. (Pubitemid 39298382)
115. Han SY, Kim CH, Kim HS, Jee YH, Song HK, Lee MH, Han KH, Kim HK, Kang YS, Han JY, Kim YS, Cha DR. Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetics rats. J Am Soc Nephrol 2006; 17: 1362-1372.
116. Takebayashi K, Matsumoto S, Aso Y, Inukai T. Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy. J Clin Endocrinol Metab 2006; 91: 2214-2217. (Pubitemid 43855008)
117. Xu Y, Osborne BW, Stanton RC. Diabetes causes inhibition of glucose-6-phosphate dehydrogenase via activation of PKA, which contributes to oxidative stress in rat kidney cortex. Am J Physiol Renal Physiol 2005; 289: 1040-1047.
118. Leopold JA, Cap A, Scribner AW, Stanton RC, Loscalzo J. Glucose-6-phosphate dehydrogenase deficiency promotes endothelial oxidant stress and decreases endothe-lial nitric oxide bioavailability. FASEB J 2001; 15: 1771-1773.
119. Leopold JA, Zhang YY, Scribner AW, Stanton RC, Loscalzo J. Glucose-6-phosphate dehydrogenase overexpression decreases endothelial cell oxidant stress and increases bioavailable nitric oxide. Arterioscler Thromb Vasc Biol 2003; 23: 411-417. (Pubitemid 36337216)
120. Xu Y, Zhang Z, Hu J, Stillman IE, Leopold JA, Handy DE, Loscalzo J, Stanton RC. Glucose-6-phosphate dehydrogenase-deficient mice have increased renal oxidative stress and increased albuminuria. FASEB J 2010; 24: 609-616.
121. Leopold JA, Dam A, Maron BA, Scribner AW, Liao R, Handy DE, Stanton RC, Pitt B, Loscalzo J. Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med 2007; 13: 189-197.
122. Viengchareun S, Le Menuet D, Martinerie L, Munier M, Pascual-Le Tallec L, Lombès M. The mineralocorticoid receptor: insights into its molecular and (patho)physiological biology. Nucl Recept Signal 2007; 5: e012.
123. Wilkinson-Berka JL, Tan G, Jaworski K, Miller AG. Identification of a retinal aldoster-one system and the protective effects of mineralocorticoid receptor antagonism on retinal vascular pathology. Circ Res 2009; 104: 124-133.
124. Castrochaves P, Cerqueira R, Pintalhao M, Leite-Moreira AF. New pathways of the renin-angiotensin system: the role of ACE2 in cardiovascular pathophysiology and therapy. Expert Opin Ther Targets 2010; 14: 485-496.
125. Oudit GY, Liu GC, Zhong J, Basu R, Chow FL, Zhou J, Loibner H, Janzek E, Schuster M, Penninger JM, Herzenberg AM, Kassiri Z, Scholey JW. Human recombinant ACE2 reduces the progression of diabetic nephropathy. Diabetes 2010; 59: 529-538.
126. Tikellis C, Johnston CI, Forbes JM, Burns WC, Thomas MC, Lew RA, Yarski M, Smith AI, Cooper ME. Identification of angiotensin converting enzyme 2 in the rodent retina. Curr Eye Res 2004; 29: 419-427. (Pubitemid 40138381)
127. Luhtala S, Vaajanen A, Oksala O, Valjakka J, Vapaatalo H. Activities of angiotensin-converting enzymes ACE1 and ACE2 and inhibition by bioactive peptides in porcine ocular tissues. J Ocul Pharmacol Ther 2009; 25: 23-28.
128. Burrell LM, Johnston CI, Tikellis C, Cooper ME. ACE2, a new regulator of the renin-angiotensin system. Trends Endocrinol Metab 2004; 15: 166-169. (Pubitemid 38510496)
129. Tikellis C, Johnston CI, Forbes JM, Burns WC, Burrell LM, Risvanis J, Cooper ME. Characterization of renal angiotensin converting enzyme 2 in diabetic nephropathy. Hypertension 2003; 41: 392-397. (Pubitemid 36314606)
130. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, Breitbart RE, Acton S. A novel angiotensin-converting enzymerelated carboxypeptidase (ACE2) converts angiotensin I to angio-tensin 1-9. Circ Res 2000; 87: E1-E9.
131. Reich HN, Oudit GY, Penninger JM, Scholey JW, Herzenberg AM. Decreased glomer-ular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease. Kidney Int 2008; 74: 1610-1616.
132. Wang G, Lai FM, Lai KB, Chow KM, Kwan CH, Li KT, Szeto CC. Discrepancy between intrarenal messenger RNA and protein expression of ACE and ACE2 in human diabetic nephropathy. Am J Nephrol 2009; 29: 524-531.
133. Wysocki J, Ye M, Soler MJ, Gurley SB, Xiao HD, Bernstein KE, Coffman TM, Chen S, Batlle D. ACE and ACE2 activity in diabetic mice. Diabetes 2006; 55: 2132-2139. (Pubitemid 44509989)
134. Shiota A, Yamamoto K, Ohishi M, Tatara Y, Ohnishi M, Maekawa Y, Iwamoto Y, Takeda M, Rakugi H. Loss of ACE2 accelerates time-dependent glomerular and tubulointer-stitial damage in streptozotocin-induced diabetic mice. Hypertens Res 2010; 33: 298-307.
135. Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T, Sraer JD. Pivotal role of the renin/ prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002; 109: 1417-1427. (Pubitemid 34596167)
136. Wilkinson-Berka JL, Heine R, Tan G, Cooper ME, Hatzopoulos KM, Fletcher EL, Binger KJ, Campbell DJ, Miller AG. RILLKKMPSV influences the vasculature, neurons and glia, and (Pro)renin receptor expression in the retina. Hypertension 2010; 55: 1454-1460.
137. Wilkinson-Berka JL, Campbell DJ. (Pro)renin receptor: a treatment target for diabetic retinopathy? Diabetes 2009; 58: 1485-1487.
138. Wilkinson-Berka JL. Prorenin and the (pro)renin receptor in ocular
139. Feldman DL, Jin L, Xuan H, Contrepas A, Zhou Y, Webb RL, Mueller DN, Feldt S, Cumin F, Maniara W, Persohn E, Schuetz H, Jan Danser AH, Nguyen G. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension 2008; 52: 130-136.
140. Hsueh WA, Baxter JD. Human prorenin. Hypertension 1991; 17: 469-477.
141. Danser AH, Van den Dorpel MA, Deinum J, Derkx FH, Franken AA, Peperkamp E, de Jong PT, Schalekamp MA. Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy. J Clin Endocrinol Metab 1989; 68: 160-167. (Pubitemid 19028740)
142. Berka JL, Stubbs AJ, Wang DZ, DiNicolantonio R, Alcorn D, Campbell DJ, Skinner SL. Renin-containing Müller cells of the retina display endocrine features. Invest Ophthal-mol Vis Sci 1995; 36: 1450-1458.
143. Campbell DJ. Critical review of prorenin and (pro)renin receptor research. Hypertension 2008; 51: 1259-1264. (Pubitemid 351555933)
144. Ichihara A, Hayashi M, Kaneshiro Y, Suzuki F, Nakagawa T, Tada Y, Koura Y, Nishiyama A, Okada H, Uddin MN, Nabi AH, Ishida Y, Inagami T, Saruta T. Inhibition of diabetic nephropathy by a decoy peptide corresponding to the 'handle' region for nonproteo-lytic activation of prorenin. J Clin Invest 2004; 114: 1128-1135. (Pubitemid 39578702)
145. Takahashi H, Ichihara A, Kaneshiro Y, Inomata K, Sakoda M, Takemitsu T, Nishiyama A, Itoh H. Regression of nephropathy developed in diabetes by (Pro)renin receptor blockade. J Am Soc Nephrol 2007; 18: 2054-2061. (Pubitemid 47041071)
146. Huang J, Siragy HM. Glucose promotes the production of interleukine-1beta and cyclooxygenase-2 in mesangial cells via enhanced (Pro)renin receptor expression. Endocrinology 2009; 150: 5557-5565.
147. Satofuka S, Ichihara A, Nagai N, Noda K, Ozawa Y, Fukamizu A, Tsubota K, Itoh H, Oike Y, Ishida S. (Pro)renin receptor-mediated signal transduction and tissue renin-angiotensin system contribute to diabetes-induced retinal inflammation. Diabetes 2009; 58: 1625-1633.
148. Tang Z, Shou I, Wang LN, Fukui M, Tomino Y. Effects of antihypertensive drugs or glycemic control on antioxidant enzyme activities in spontaneously hypertensive rats with diabetes. Nephron 1997; 76: 323-330. (Pubitemid 27296536)
149. Ogawa S, Kobori H, Ohashi N, Urushihara M, Nishiyama A, Mori T, Ishizuka T, Nako K, Ito S. Angiotensin II Type 1 receptor blockers reduce urinary angiotensinogen excretion and the levels of urinary markers of oxidative stress and inflammation in patients with Type 2 Diabetic nephropathy. Biomark Insights 2009; 4: 97-102.
150. United Kingdom Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
151. Ruggenenti P, Cravedi P, Remuzzi G, Medscape. The RAAS in the pathogenesis and treatment of diabetic nephropathy. Nat Rev Nephrol 2010; 6: 319-330.
152. Wilkinson-Berka JL. Angiotensin and diabetic retinopathy. Int J Biochem Cell Biol 2006; 38: 752-765. (Pubitemid 43372053)
153. Silva PS, Cavallerano JD, Sun JK, Aiello LM, Aiello LP. Effect of systemic medications on onset and progression of diabetic retinopathy. Nat Rev Endocrinol 2010; 6: 494-508.
154. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580-591. (Pubitemid 351214285)
155. Nakamura T, Fujiwara N, Sugaya T, Ueda Y, Koide H. Effect of red wine on urinary protein, 8-hydroxydeoxyguanosine, and liver-type fatty acid-binding protein excretion in patients with diabetic nephropathy. Metabolism 2009; 58: 1185-1190.
156. Taubert D, Roesen R, Lehmann C, Jung N, Schömig E. Effects of low habitual cocoa intake on blood pressure and bioactive nitric oxide: a randomized controlled trial. JAMA 2007; 298: 49-60. (Pubitemid 47026770)
157. Mustata GT, Rosca M, Biemel KM, Reihl O, Smith MA, Viswanathan A, Strauch C, Du Y, Tang J, Kern TS, Lederer MO, Brownlee M, Weiss MF, Monnier VM. Paradoxical effects of green tea (Camellia sinensis) and antioxidant vitamins in diabetic rats: improved retinopathy and renal mitochondrial defects but deterioration of collagen matrix glycoxidation and cross-linking. Diabetes 2005; 54: 517-526.